 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| RC108 / Rongchang Pharma
Enrollment open, Combination therapy, Metastases: RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC (clinicaltrials.gov) - Nov 27, 2023
P1/2, N=106, Recruiting, Sponsor: RemeGen Co., Ltd.
Not yet recruiting --> Recruiting
- |||| RC108 / Rongchang Pharma
New P1/2 trial, Combination therapy, Metastases: RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC (clinicaltrials.gov) - Apr 20, 2023
P1/2, N=106, Not yet recruiting, Sponsor: RemeGen Co., Ltd.
- |||| RC108 / Rongchang Pharma
Enrollment open, Metastases: A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor (clinicaltrials.gov) - Mar 7, 2023
P2, N=240, Recruiting, Sponsor: RemeGen Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| RC108 / Rongchang Pharma
New P2 trial, Metastases: A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor (clinicaltrials.gov) - Nov 29, 2022
P2, N=240, Not yet recruiting, Sponsor: RemeGen Co., Ltd.
- || RC108 / Rongchang Pharma
Enrollment open, Metastases: A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov) - Apr 20, 2021
P1, N=32, Recruiting, Sponsor: RemeGen
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || RC108 / Rongchang Pharma
New P1 trial, Metastases: A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov) - Nov 4, 2020
P1, N=32, Not yet recruiting, Sponsor: RemeGen